Document is current
Any future updates will be listed below
-
Authors
Ausserwöger, Hannes https://orcid.org/0000-0003-0762-8872
Scrutton, Rob https://orcid.org/0009-0008-0012-0703
Fischer, Charlotte M.
Sneideris, Tomas https://orcid.org/0000-0001-5285-871X
Qian, Daoyuan https://orcid.org/0000-0002-8539-3346
de Csilléry, Ella https://orcid.org/0000-0001-5917-9349
Baronaite, Ieva https://orcid.org/0009-0006-5515-8528
Saar, Kadi L.
Białek, Alan Z.
Oeller, Marc https://orcid.org/0000-0003-0597-5950
Krainer, Georg
Franzmann, Titus M. https://orcid.org/0000-0002-4281-7209
Wittmann, Sina https://orcid.org/0000-0002-0074-5331
Iglesias-Artola, Juan M. https://orcid.org/0000-0002-0409-795X
Invernizzi, Gaetano
Hyman, Anthony A. https://orcid.org/0000-0003-0851-704X
Alberti, Simon https://orcid.org/0000-0003-4017-6505
Lorenzen, Nikolai
Knowles, Tuomas P. J. https://orcid.org/0000-0002-7879-0140
-
Funding
Funding for this research was provided by:
Frances and Augustus Newman Foundation
- License Information
-
More Information
Article History
Received: 11 July 2024
Accepted: 27 November 2025
First Online: 29 January 2026
Competing interests
: T.P.J.K. is the CTO of Transition Bio Inc., G.I. and N.L. are employees of Novo Nordisk, and S.A. and A.A.H. are members of the scientific advisory board of Dewpoint Therapeutics Inc. The work reported here was not influenced by these affiliations. The other authors declare no competing interests.
